Expert Interviews

A study presented last month at ASTRO found that better radiation outcomes for head and neck cancer were associated with higher facility volume.

In leukemias, cyclic adenosine monophosphate (cAMP) can play a role in cancer cell maturation and can be both pro- and antiapoptotic.

Several anti-malarial and anti-fungal drugs might be able to overcome a previously unexploited mechanism that allows some leukemia cells to escape programmed cell death.

In this video we discuss the initial symptoms and diagnosis of multiple myeloma as well as upfront treatment with autologous stem cell transplantation and newer agents.

In this video we discuss the goals of shared-decision making in hematologic malignancies and touch upon different scenarios where its use may be appropriate.

This video explores a study that found telephone-based genetic counseling for women at risk of hereditary breast and ovarian cancers was noninferior to in-person counseling, with no significant adverse effects on long-term outcomes.

In this video we discuss the use of concurrent immunotherapy and stereotactic radiosurgery for treatment of melanoma brain metastases.

In this video we discuss the continuation of nivolumab after tumor progression in patients with advanced renal cell carcinoma in the CheckMate 025 trial.

In this video we discuss the results of a phase III trial that studied upfront high-dose chemotherapy plus autologous stem cell transplantation (ASCT) compared to chemotherapy alone and bortezomib in newly diagnosed multiple myeloma.

In this video we discuss 3-year results of the COMBI-d trial, which studied dabrafenib and trametinib in patients with unresectable or metastatic BRAF-mutated melanoma.

In this video we discuss the use of biomarker-guided treatment in phase I trials, which can yield high response rates.

In this video we discuss promising results of the anti–PD-L1 agent avelumab in patients with metastatic Merkel cell carcinoma who had previously been treated with chemotherapy.

In this video we discuss how palliative care early on in the process of treating patients with cancer led to an improvement in depressive symptoms and quality of life among family caregivers.

A retrospective analysis of a phase III clinical trial found that the physical location of the primary tumor predicts survival in patients with metastatic colorectal cancer.

In this video Dr. Odunsi discusses a new study that found that higher T-cell diversity in ovarian cancer is associated with poor overall survival.

In this peer-to-peer discussion Dr. Grivas and Dr. Palmbos examine the role of neoadjuvant chemotherapy in bladder cancer and weigh the various trial data guiding these treatment decisions.

In this peer-to-peer discussion, Dr. Loeb and Dr. Choyke discuss new developments in active surveillance for prostate cancer.

In this video we discuss a large-scale genomic analysis that found that patterns of genetic changes detected in circulating tumor DNA mirror those identified in tumor tissue biopsies.

Results of the IMvigor210 clinical trial found that atezolizumab is effective in patients with locally advanced or metastatic cisplatin-ineligible urothelial carcinoma.

The ESPAC-4 trial found that adding capecitabine to gemcitabine in patients with resected pancreatic cancer resulted in an improved estimated 5-year survival rate.